Menu
Recruiting NCT03438474

Endometrial Cancer Lymphadenectomy Trial

No phase Interventional Cancer of Endometrium Stage I Cancer of Endometrium Stage II

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE).
Who it may be relevant to
Registry conditions: Cancer of Endometrium Stage I, Cancer of Endometrium Stage II. Basic parameters: 18 years — 75 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany, Japan, South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Pelvic and Para-aortic Lymphadenectomy in Patients With Stage I or II Endometrial Cancer With High Risk of Recurrence

Overview

The primary aim of this trial is to ascertain whether or not systematic pelvic and para-aortic lymphadenectomy (LNE) does have a significant impact on overall survival (OS) in patients with endometrial cancer (EC) FIGO Stages I or II and high risk of recurrence. Secondary aims will be to evaluate the effect of LNE on disease free survival (DFS) and quality of life, as well as the complications and side effects of LNE and the number of resected lymphnodes. 640 patients with histologically confirmed EC with high risk of recurrence (stage pT1b - pT2, all histological subtypes; pT1a, G3 endometrioid or serous or clear cell EC or carcinosarcomas) will be randomized. In Arm A, a total hysterectomy and bilateral salpingo-oophorectomy and in case of serous or clear cell EC additionally an omentectomy will be performed. In arm B in addition a systematic pelvic and para-aortic LNE up to the level of the left renal vein will be performed.

Interventions

  • Procedure Standard surgical procedure for endometrial cancer
    total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
  • Procedure systematic lymphadenectomy (LNE)
    systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels

Primary outcome measures

  • Overall survival (OS) [Time frame: 60 months]
Secondary outcome measures (6)
  • Disease free survival (DFS) [Time frame: 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months]
  • Disease specific survival (DSS) [Time frame: 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months]
  • Assessment of serious complications [Time frame: during surgery, at hospital discharge, day 60, 6 months, 9 months, 12 months]
  • EORTC QLQ-C30 [Time frame: Baseline, at hospital discharge, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months]
  • EORTC QLQ-EN24 [Time frame: Baseline, at hospital discharge, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months]
  • Number of resected lymph nodes [Time frame: during surgery]

Eligibility criteria

Inclusion criteria

  • histologically confirmed EC of clinical stages T1b and T2 (all histological types) and stage T1a G3 type 1 (endometrioid, endometriod with squamous differentiation, mucinous) or type 2 tumors (any percentage of serous or clear cell component) or carcinosarcoma
  • a) no previous surgery concerning EC (primary surgery) or b) surgery after hysterectomy (e.g. for presumed low risk endometrial cancer) is allowed within 8 weeks after hysterectomy if no LNE was performed (secondary surgery)
  • absence of bulky lymph nodes
  • performance status ECOG 0-1
  • age 18 - 75 years
  • written informed consent
  • adequate compliance

Exclusion criteria

  • stage pT1a, G1 or G2 tumors of type 1 histology
  • sarcomas (except for carcinosarcoma = malignant mixed Müllerian tumor)
  • EC of FIGO stages III or IV (except for microscopical lymph node metastases)
  • evidence of extrauterine disease by visual inspection
  • recurrent EC
  • preceding chemo-, radio, or endocrine therapy for EC
  • any concomitant disease not allowing surgery including lymphadenectomy and/or chemotherapy
  • any medical history indicating excessive peri-operative risk
  • any current medication containing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents)
  • any known disorder or circumstances making participation in trial and follow-up questionable. Insufficient compliance is expected.
  • patients with second malignancies if disease or treatment might have an impact on the patient's prognosis
  • known HIV-infection or AIDS
  • simultaneous participation in other clinical trials if not permitted by the steering committee (translational or QoL studies not interfering with the objectives of ECLAT are allowed)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Germany · 58 centers
  • Ostalb-Klinikum Aalen, Frauenklinik — Aalen
  • Klinikum St. Marien Amberg, Frauenklinik — Amberg
  • Klinikum Ansbach, Klinikum Ansbach — Ansbach
  • Universitätsklinikum Augsburg, Frauenklinik — Augsburg
  • Hochtaunus-Kliniken gGmbH, Frauenklinik — Bad Homburg
  • Sozialstiftung Bamberg, Klinikum am Bruderwald, Klinik für Frauenheilkunde — Bamberg
  • SANA Klinikum Lichtenberg, Oskar-Ziehten-Krankenhaus, Frauenklinik — Berlin
  • Vivantes Auguste-Viktoria-Klinikum, Klinik für Gynäkologie und Geburtsmedizin — Berlin
  • … and 50 more centers
Japan · 2 centers
  • Okayama University Hospital — Okayama
  • Saitama Medical University International Medical Center — Saitama
South Korea · 1 center
  • Seoul National University Hospital, Department of Obstetrics & Gynecology — Seoul

Publications

  • Leone Roberti Maggiore U, Spano Bascio L, Alboni C, Chiarello G, Savelli L, Bogani G, Martinelli F, Chiappa V, Ditto A, Raspagliesi F. Sentinel lymph node biopsy in endometrial cancer: When, how and in which patients. Eur J Surg Oncol. 2024 Mar;50(3):107956. doi: 10.1016/j.ejso.2024.107956. Epub 2024 Jan 17. PMID 38286085
  • Emons G, Kim JW, Weide K, de Gregorio N, Wimberger P, Trillsch F, Gabriel B, Denschlag D, Kommoss S, Aydogdu M, Papathemelis T, Gropp-Meier M, Muallem MZ, Kuhn C, Muller A, Frank M, Weigel M, Bronger H, Lampe B, Rau J, Schade-Brittinger C, Harter P. Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high r PMID 34226291

Identifiers

NCT: NCT03438474 · AGO-OP.6 KKS 228

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗